Abstract

Mitotic counts in the World Health Organization (WHO) grading system have narrow cutoff values. True mitotic figures, however, are not always distinguishable from apoptotic bodies and darkly stained nuclei, complicating the ability of the WHO grading system to diagnose well-differentiated neuroendocrine tumors (NETs). The mitosis-specific marker phosphohistone H3 (PHH3) can identify true mitoses and grade tumors reliably. The aim of this study was to investigate the correspondence of tumor grades, as determined by PHH3 mitotic index (MI) and mitotic counts according to WHO criteria, and to determine the clinically relevant cutoffs of PHH3 MI in rectal and nonrectal gastrointestinal NETs. Mitotic counts correlated with both the Ki-67 labeling index and PHH3 MI, but the correlation with PHH3 MI was slightly higher. The PHH3 MI cutoff ≥4 correlated most closely with original WHO grades for both rectal NETs. A PHH3 MI cutoff ≥4, which could distinguish between G1 and G2 tumors, was associated with disease-free survival in patients with rectal NETs, whereas that cutoff value showed marginal significance for overall survival in patient with rectal NETs. In conclusion, the use of PHH3 ≥4 correlated most closely with original WHO grades.

Highlights

  • Neuroendocrine tumors (NETs) are uncommon, heterogeneous groups of neoplasms, with most (54%) developing in the gastrointestinal tract [1,2,3,4]

  • This study was designed to explore the diagnostic utility of phosphohistone H3 (PHH3) mitotic index (MI) as an ancillary mitotic marker and the clinically relevant cutoff value of PHH3 MI in patients with gastrointestinal well-differentiated NETs, by comparing World Health Organization (WHO) grades and WHO grades modified by PHH3 MI

  • We found that a PHH3 MI cutoff of 4 was most similar to WHO grade

Read more

Summary

Introduction

Neuroendocrine tumors (NETs) are uncommon, heterogeneous groups of neoplasms, with most (54%) developing in the gastrointestinal tract [1,2,3,4]. The incidence and prognosis of gastrointestinal NETs depend on the tumor primary site, with the highest frequencies observed in the rectum (17.7%), small intestine (17.3%), and colon (10.1%), followed by the stomach (6.0%) and appendix (3.1%) and with survival ranging from 6 months to more than 20 years [1,2,3,4]. Gastrointestinal NETs largely arise from enterochromaffin and enteroglucagon cells found in the lamina propria and BioMed Research International (a) (b) (c) (d) (e) (f ) (g) (h). Distant metastasis resulting from unexpected tumor aggressiveness is of clinical concern in patients with welldifferentiated NETs [8,9,10,11]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call